INmune Bio Inc. Common stock (INMB) is a publicly traded Healthcare sector company. As of May 21, 2026, INMB trades at $1.45 with a market cap of $39.61M and a P/E ratio of -0.75. INMB moved -0.71% today. Year to date, INMB is -5.37%; over the trailing twelve months it is -81.64%. Its 52-week range spans $1.09 to $11.64. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces INMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes INMB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $1.45 |
| Market Cap | $39.61M |
| P/E Ratio | -0.75 |
| EPS | $-1.86 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.64 |
| 52-Week Low | $1.09 |
| Volume | 539 |
| Avg Volume | 0 |
| Revenue (TTM) | $50.00K |
| Net Income | $-45.93M |
| Gross Margin | 0.00% |
3 analysts cover INMB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.